ReviewInternational journal of molecular sciences2014
Platelets: still a therapeutical target for haemostatic disorders.
Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Identification of molecular heterogeneity in telomere maintenance pathway of aplastic anemia.Molecular biology reports · 2025Article
- Unveiling the role of lipid metabolism in haemorrhagic disorders: genetic insights and therapeutic perspectives.Thrombosis journal · 2025Article
- Synthesis, Docking, and DFT Studies on Novel Schiff Base Sulfonamide Analogues as Selective COX-1 Inhibitors with Anti-Platelet Aggregation Activity.Pharmaceuticals (Basel, Switzerland) · 2024Article
- PI3K Isoform Signalling in Platelets.Current topics in microbiology and immunology · 2022Article
- Platelet lysate for COVID-19 pneumonia-a newer adjunctive therapeutic avenue.Stem cell investigation · 2021Review
- ROS in Platelet Biology: Functional Aspects and Methodological Insights.International journal of molecular sciences · 2020Review
- Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.Current atherosclerosis reports · 2017Review
- Recent advancements in erythrocytes, platelets, and albumin as delivery systems.OncoTargets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets are cytoplasmatic fragments from bone marrow megakaryocytes present in blood. In this work, we review the basis of platelet mechanisms, their participation in syndromes and in arterial thrombosis, and their potential as a target for designing new antithrombotic agents. The option of new biotechnological sources is also explored.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.